News stories about Otonomy (NASDAQ:OTIC) has been popular fairly positive quite recently, Accern media research reports. Accern pointing out the bullish and bearish media analysis by examining larger than 20 Million SEC financial documents and social media sites sources in real-time. Accern grades analysis of large corporations ranging from negative 1 to +1, with ranks nearest to 1 is considered more positive. Otonomy earned a Day to day impact score of 0.12 on Accern’s range. Accern also gave media analysis about the biopharmaceutical company a media impact point of 44.9665040870086 out of 100, pointing that most recent media headlines is fairly unlikely to affect on the stock’s share value upcoming future.
Quite a few analysts have quite recently weighed in on OTIC. Piper Jaffray Companies cut shares of Otonomy from an “overweight” recommendation to a “neutral” recommendation and reduced their target price for the share from $32.00 to $8.00 in a study note published on Wed, Aug 30th. J P Morgan Chase & Co cut shares of Otonomy from an “overweight” recommendation to a “neutral” recommendation and reduced their target price for the share from $28.00 to $8.00 in a study note published on Wed, Aug 30th. Cowen and Company reiterated an “outperform” recommendation and given a $55.00 target price on stock of Otonomy in a study note published on Wed, Aug 23rd. Research firm Zacks lifted stocks of Otonomy from a “sell” recommendation to a “hold” recommendation in a analysis note on Tue, Jul 18th. Lastly, BidaskClub cut shares of Otonomy from a “buy” recommendation to a “hold” recommendation in a analysis note on Fri morning, Aug 11th. 1 expert has recommended the share with a sell recommendation, four have published a hold recommendation and two have published a buy recommendation to The corporation. the share presently has a average recommendation of “Hold” and an average price objective of $10.00.
A few press stories that May have effected Accern trend Analysis’s scoring:
Otonomy (NASDAQ OTIC) transacted up 1.47% throughout intraday market trading on early Fri, reaching $3.45. 1,062,300 stocks of the firms shares transacted hands. The corporation has a fifty day SMA of $7.24 and a two hundred SMA of $13.27. The stock’s market valuation is $104.55 M. Otonomy has a 1 year low of $3.15 has a 1 year high of $21.15.
Otonomy (NASDAQ:OTIC) previously issued its earnings report on Early Thur, Aug 3rd. The biopharmaceutical business posted ($0.77) Earnings per share for the period, reaching the Zacks’ average forecast of ($0.80) by $0.03. the business reported sales of $0.33 M for the period compared to analysts’ anticipations of $0.43 M. Otonomy had a lower negative return on equity of 57.43% and a negative net profit margin of 8,172.38%. The company’s for the quarter end, revenue was upwards of 312.5% compared with the same period in the prior year. For the same quarter from the prior fiscal year, firm reported ($0.98) Earnings Per Share. on consensus, analysts expect that Otonomy to post ($3.23) earnings per share for the full year.